The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pertussis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pertussis bone marrow transplant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-64
* BMT at the QEII Health Sciences Centre
* BMT within last 12 months
* Able to read and write English language
* Able to give consent

Exclusion Criteria

* Active infection
* Active GVHD
* Recent IVIG
* Allergy to components of vaccine
* Diphtheria or tetanus vaccination within 18 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Monique L MacFarlane Conrad, MSc

Role: PRINCIPAL_INVESTIGATOR

Dalhousie University Medical School

Shelly McNeil, MD

Role: STUDY_DIRECTOR

Queen Elizabeth II Health Sciences Centre

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

qeii

Identifier Type: -

Identifier Source: org_study_id